Harmony Biosciences Holdings, Inc. (HRMY) stock
HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)
Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –
Harmony Biosciences cash
Cash and short-term investments held at the end of each period.
Harmony Biosciences's cash was $667.79M at Jun 30, 2026. For fiscal 2025 it was $775.34M, up 65.9% from the year before. The highest annual figure on record is $775.34M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $775.34M | +65.9% |
| FY2024 | Dec 31, 2024 | $467.46M | +32.2% |
| FY2023 | Dec 31, 2023 | $353.73M | +9.2% |
| FY2022 | Dec 31, 2022 | $323.87M | +37.8% |
| FY2021 | Dec 31, 2021 | $235.06M | +2.5% |
| FY2020 | Dec 31, 2020 | $229.38M | +810.0% |
| FY2019 | Dec 31, 2019 | $25.21M | -70.0% |
| FY2018 | Dec 31, 2018 | $84.02M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $667.79M | +18.1% |
| Q1 FY2026 | Mar 31, 2026 | $640.92M | +26.4% |
| Q4 FY2025 | Dec 31, 2025 | $775.34M | +65.9% |
| Q3 FY2025 | Sep 30, 2025 | $672.58M | +63.7% |
| Q2 FY2025 | Jun 30, 2025 | $565.54M | +62.9% |
| Q1 FY2025 | Mar 31, 2025 | $507.22M | +36.1% |
| Q4 FY2024 | Dec 31, 2024 | $467.46M | +32.2% |
| Q3 FY2024 | Sep 30, 2024 | $410.75M | +10.7% |
| Q2 FY2024 | Jun 30, 2024 | $347.18M | -6.5% |
| Q1 FY2024 | Mar 31, 2024 | $372.62M | +8.1% |
| Q4 FY2023 | Dec 31, 2023 | $353.73M | +9.2% |
| Q3 FY2023 | Sep 30, 2023 | $370.92M | +20.2% |
| Q2 FY2023 | Jun 30, 2023 | $371.23M | +45.6% |
| Q1 FY2023 | Mar 31, 2023 | $344.63M | +53.0% |
| Q4 FY2022 | Dec 31, 2022 | $323.87M | +37.8% |
| Q3 FY2022 | Sep 30, 2022 | $308.51M | +62.0% |
| Q2 FY2022 | Jun 30, 2022 | $254.92M | +58.9% |
| Q1 FY2022 | Mar 31, 2022 | $225.25M | +58.7% |
| Q4 FY2021 | Dec 31, 2021 | $235.06M | +2.5% |
| Q3 FY2021 | Sep 30, 2021 | $190.45M | -14.4% |
| Q2 FY2021 | Jun 30, 2021 | $160.44M | +108.3% |
| Q1 FY2021 | Mar 31, 2021 | $141.92M | +96.4% |
| Q4 FY2020 | Dec 31, 2020 | $229.38M | +810.0% |
| Q3 FY2020 | Sep 30, 2020 | $222.49M | +118.1% |
| Q2 FY2020 | Jun 30, 2020 | $77.03M | -8.3% |
| Q1 FY2020 | Mar 31, 2020 | $72.27M | – |
| Q4 FY2019 | Dec 31, 2019 | $25.21M | – |
| Q3 FY2019 | Sep 30, 2019 | $102.02M | – |
| Q4 FY2018 | Dec 31, 2018 | $84.02M | – |
See a number that looks wrong?